Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Alan Meds vs Vaylen

Both scored on the same six-factor Match Score. Vaylen wins this matchup with a 87 to 86 edge — a photo finish.

Alan Meds

#7 · Grade B+

Budget shoppers who want an oral/sublingual route without giving up nationwide access.

Visit Alan Meds
VS
Higher Match Score

Vaylen

#5 · Grade B+

People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.

Visit Vaylen

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
93
82
Speed to Start
88
88
Formulary Match
86
94
Support Level
82
86
Flexibility
84
86
Transparency
80
88

Price, coverage & formulary

DetailAlan MedsVaylen
Semaglutide$99/mo$179/mo
Tirzepatide$145/mo$239/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Match Score86 · B+87 · B+
Winner: Vaylen

Vaylen edges out Alan Meds, 87 to 86 on the default Match Score. One of the widest formularies on the board — both molecules, an oral route, and brand access, all nationwide.

Alan Meds is still a fair pick if its strengths line up with yours — best for: Budget shoppers who want an oral/sublingual route without giving up nationwide access.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Alan Meds reviewFull Vaylen review

More head-to-heads

Or browse alternatives to Vaylen and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.